Individualized Dosing Patterns in the Treatment of Older Patients with Gastrointestinal Stromal Tumors: Results of a Registry-Based Observational National Cohort Study Including 871 Patients.
Journal
Drugs & aging
ISSN: 1179-1969
Titre abrégé: Drugs Aging
Pays: New Zealand
ID NLM: 9102074
Informations de publication
Date de publication:
20 Dec 2023
20 Dec 2023
Historique:
accepted:
21
11
2023
medline:
21
12
2023
pubmed:
21
12
2023
entrez:
20
12
2023
Statut:
aheadofprint
Résumé
While the effectiveness of tyrosine kinase inhibitors (TKIs) seems similar in older patients with gastrointestinal stromal tumors (GIST) compared with younger patients, toxicities in older patients treated with TKIs more often lead to discontinuation of treatment. To better understand the age-related pharmacology and pharmacodynamic differences in patients with GIST treated with TKIs, the primary aim of this study was to evaluate TKI dosing patterns in older patients with GIST, while the secondary aims were to evaluate differences in imatinib trough plasma concentrations between age groups and to compare the overall survival (OS) in patients with and without dose reductions in all treatment lines in a palliative setting. Patients (18 years of age or older) with histologically proven GIST diagnosed between January 2009 and June 2021 and treated with one or more lines of TKIs were selected from the Dutch GIST Registry (DGR) database. Age groups were divided into younger patients (age <70 years) and older patients (age ≥70 years). All imatinib trough plasma concentrations of blood withdrawals taken from initiation of imatinib until a maximum of 1 year of treatment with imatinib were collected. Reasons for first adjustment of treatment were classified as adverse event, dose modification, progressive disease and other reasons. The next treatment steps after first adjustment of treatment were defined as dose escalation, dose reduction, dose interruption, or end of treatment. The association of dose reduction and OS was analyzed using the landmark approach. Overall, 871 patients were included in this study, including 577 younger patients and 294 older patients. Older patients more often had an adverse event as the reason for first adjustment of treatment with both imatinib (45.6%; p < 0.001) and sunitinib (58.6%; p = 0.224) compared with younger patients (19.5% and 42.7%, respectively). Adjustment of imatinib and sunitinib after starting on a standard dose because of an adverse event most often resulted in dose reduction in both age groups. Median trough plasma concentrations of all samples taken within the first year after initiation of imatinib were higher in older patients (1228 ng/mL, interquartile range [IQR] 959-1687) compared with younger patients (1035 ng/mL [IQR 773-1377]; p < 0.001). No significant differences were seen between OS in patients with or without dose reduction in all treatment lines (imatinib: p = 0.270; sunitinib: p = 0.547; and regorafenib: p = 0.784). Older patients showed higher imatinib trough plasma concentrations compared with younger patients and also had earlier and more often adverse events as the reason for first adjustment of treatment with imatinib followed by dose reduction. However, in a landmark analysis, patients with imatinib dose reductions had no poorer outcomes compared with patients not requiring a dose reduction.
Sections du résumé
BACKGROUND
BACKGROUND
While the effectiveness of tyrosine kinase inhibitors (TKIs) seems similar in older patients with gastrointestinal stromal tumors (GIST) compared with younger patients, toxicities in older patients treated with TKIs more often lead to discontinuation of treatment.
OBJECTIVE
OBJECTIVE
To better understand the age-related pharmacology and pharmacodynamic differences in patients with GIST treated with TKIs, the primary aim of this study was to evaluate TKI dosing patterns in older patients with GIST, while the secondary aims were to evaluate differences in imatinib trough plasma concentrations between age groups and to compare the overall survival (OS) in patients with and without dose reductions in all treatment lines in a palliative setting.
METHODS
METHODS
Patients (18 years of age or older) with histologically proven GIST diagnosed between January 2009 and June 2021 and treated with one or more lines of TKIs were selected from the Dutch GIST Registry (DGR) database. Age groups were divided into younger patients (age <70 years) and older patients (age ≥70 years). All imatinib trough plasma concentrations of blood withdrawals taken from initiation of imatinib until a maximum of 1 year of treatment with imatinib were collected. Reasons for first adjustment of treatment were classified as adverse event, dose modification, progressive disease and other reasons. The next treatment steps after first adjustment of treatment were defined as dose escalation, dose reduction, dose interruption, or end of treatment. The association of dose reduction and OS was analyzed using the landmark approach.
RESULTS
RESULTS
Overall, 871 patients were included in this study, including 577 younger patients and 294 older patients. Older patients more often had an adverse event as the reason for first adjustment of treatment with both imatinib (45.6%; p < 0.001) and sunitinib (58.6%; p = 0.224) compared with younger patients (19.5% and 42.7%, respectively). Adjustment of imatinib and sunitinib after starting on a standard dose because of an adverse event most often resulted in dose reduction in both age groups. Median trough plasma concentrations of all samples taken within the first year after initiation of imatinib were higher in older patients (1228 ng/mL, interquartile range [IQR] 959-1687) compared with younger patients (1035 ng/mL [IQR 773-1377]; p < 0.001). No significant differences were seen between OS in patients with or without dose reduction in all treatment lines (imatinib: p = 0.270; sunitinib: p = 0.547; and regorafenib: p = 0.784).
CONCLUSION
CONCLUSIONS
Older patients showed higher imatinib trough plasma concentrations compared with younger patients and also had earlier and more often adverse events as the reason for first adjustment of treatment with imatinib followed by dose reduction. However, in a landmark analysis, patients with imatinib dose reductions had no poorer outcomes compared with patients not requiring a dose reduction.
Identifiants
pubmed: 38123766
doi: 10.1007/s40266-023-01084-8
pii: 10.1007/s40266-023-01084-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80. https://doi.org/10.1126/science.279.5350.577 .
doi: 10.1126/science.279.5350.577
pubmed: 9438854
Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology. 2004;127:294–9. https://doi.org/10.1053/j.gastro.2004.02.021 .
doi: 10.1053/j.gastro.2004.02.021
pubmed: 15236194
Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:923–34. https://doi.org/10.1016/S1470-2045(20)30168-6 .
doi: 10.1016/S1470-2045(20)30168-6
pubmed: 32511981
pmcid: 8383051
Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, et al. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv68–78. https://doi.org/10.1093/annonc/mdy095 .
doi: 10.1093/annonc/mdy095
pubmed: 29846513
Klug LR, Corless CL, Heinrich MC. Inhibition of KIT tyrosine kinase activity: two decades after the first approval. J Clin Oncol. 2021;39:1674–86. https://doi.org/10.1200/jco.20.03245 .
doi: 10.1200/jco.20.03245
pubmed: 33797935
pmcid: 8274803
Reichardt P, Kang YK, Rutkowski P, Schuette J, Rosen LS, Seddon B, et al. Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015;121:1405–13. https://doi.org/10.1002/cncr.29220 .
doi: 10.1002/cncr.29220
pubmed: 25641662
Mohammadi M, Jansen-Werkhoven TM, Ijzerman NS, den Hollander D, Bleckman RF, Oosten AW, et al. Dutch Gastrointestinal Stromal Tumor (GIST) registry data comparing sunitinib with imatinib dose escalation in second-line advanced Non-KIT Exon 9 mutated GIST patients. Target Oncol. 2022;17:627–34. https://doi.org/10.1007/s11523-022-00926-6 .
doi: 10.1007/s11523-022-00926-6
pubmed: 36374447
pmcid: 9684294
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302. https://doi.org/10.1016/S0140-6736(12)61857-1 .
doi: 10.1016/S0140-6736(12)61857-1
pubmed: 23177515
Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620–5. https://doi.org/10.1200/JCO.2007.13.4403 .
doi: 10.1200/JCO.2007.13.4403
pubmed: 18235121
Blay JY. Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. Ann Oncol. 2010;21:208–15. https://doi.org/10.1093/annonc/mdp291 .
doi: 10.1093/annonc/mdp291
pubmed: 19675092
Chamberlain F, Farag S, Williams-Sharkey C, Collingwood C, Chen L, Mansukhani S, et al. Toxicity management of regorafenib in patients with gastro-intestinal stromal tumour (GIST) in a tertiary cancer centre. Clin Sarcoma Res. 2020;10:1. https://doi.org/10.1186/s13569-019-0123-4 .
doi: 10.1186/s13569-019-0123-4
pubmed: 31911828
pmcid: 6942401
Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, et al. Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: the PERSIST-5 clinical trial. JAMA Oncol. 2018;4: e184060. https://doi.org/10.1001/jamaoncol.2018.4060 .
doi: 10.1001/jamaoncol.2018.4060
pubmed: 30383140
pmcid: 6440723
DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013;258:422–9. https://doi.org/10.1097/SLA.0b013e3182a15eb7 .
doi: 10.1097/SLA.0b013e3182a15eb7
pubmed: 23860199
Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014;32:1563–70. https://doi.org/10.1200/jco.2013.51.2046 .
doi: 10.1200/jco.2013.51.2046
pubmed: 24638003
pmcid: 4026579
Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–72. https://doi.org/10.1001/jama.2012.347 .
doi: 10.1001/jama.2012.347
pubmed: 22453568
Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, et al. Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res. 2011;17:406–15. https://doi.org/10.1158/1078-0432.Ccr-10-2250 .
doi: 10.1158/1078-0432.Ccr-10-2250
pubmed: 21163869
Ijzerman NS, Groenland SL, Koenen AM, Kerst M, van der Graaf WTA, Rosing H, et al. Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours—results from daily clinical practice. Eur J Cancer. 2020;136:140–8. https://doi.org/10.1016/j.ejca.2020.05.025 .
doi: 10.1016/j.ejca.2020.05.025
pubmed: 32688207
Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46. https://doi.org/10.1016/j.canep.2015.10.031 .
doi: 10.1016/j.canep.2015.10.031
pubmed: 26618334
Dudzisz-Śledź M, Bylina E, Teterycz P, Rutkowski P. Treatment of Metastatic Gastrointestinal Stromal umors (GIST): a focus on older patients. Drugs Aging. 2021;38:375–96. https://doi.org/10.1007/s40266-021-00841-x .
doi: 10.1007/s40266-021-00841-x
pubmed: 33651369
pmcid: 8096750
Wildiers H, Glas N. Anticancer drugs are not well tolerated in all older patients with cancer. Lancet Healthy Longevity. 2020;1:e43–7. https://doi.org/10.1016/S2666-7568(20)30001-5 .
doi: 10.1016/S2666-7568(20)30001-5
pubmed: 36094187
Shrestha A, Martin C, Burton M, Walters S, Collins K, Wyld L. Quality of life versus length of life considerations in cancer patients: a systematic literature review. Psychooncology. 2019;28:1367–80. https://doi.org/10.1002/pon.5054 .
doi: 10.1002/pon.5054
pubmed: 30838697
pmcid: 6619389
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. https://doi.org/10.1016/0021-9681(87)90171-8 .
doi: 10.1016/0021-9681(87)90171-8
pubmed: 3558716
Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times. Ther Drug Monit. 2009;31:579–84. https://doi.org/10.1097/FTD.0b013e3181b2c8cf .
doi: 10.1097/FTD.0b013e3181b2c8cf
pubmed: 19730279
Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, et al. Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter? Br J Clin Pharmacol. 2018;84:2770–8. https://doi.org/10.1111/bcp.13725 .
doi: 10.1111/bcp.13725
pubmed: 30068020
pmcid: 6256014
Machado-Aranda D, Malamet M, Chang YJ, Jacobs MJ, Ferguson L, Silapaswan S, et al. Prevalence and management of gastrointestinal stromal tumors. Am Surg. 2009;75:55–60.
doi: 10.1177/000313480907500112
pubmed: 19213398
Fentiman IS, Tirelli U, Monfardini S, Schneider M, Festen J, Cognetti F, et al. Cancer in the elderly: why so badly treated? Lancet. 1990;335:1020–2. https://doi.org/10.1016/0140-6736(90)91075-l .
doi: 10.1016/0140-6736(90)91075-l
pubmed: 1970072
Morgan CJ. Landmark analysis: a primer. J Nucl Cardiol. 2019;26:391–3. https://doi.org/10.1007/s12350-019-01624-z .
doi: 10.1007/s12350-019-01624-z
pubmed: 30719655
R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. (2020). Available at: https://www.R-project.org/ .
Corporiation IBM. Released 2017. IBM SPSS statistics for windows, version 25.0. Armonk: IBM Corporation; 2017.
Italiano A, Saada E, Cioffi A, Poulette S, Bouchet S, Molimard M, et al. Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications. Target Oncol. 2013;8:295–300. https://doi.org/10.1007/s11523-012-0243-8 .
doi: 10.1007/s11523-012-0243-8
pubmed: 23263874
Chen Y, Dong X, Wang Q, Liu Z, Dong X, Shi S, et al. Factors influencing the steady-state plasma concentration of imatinib mesylate in patients with gastrointestinal stromal tumors and chronic myeloid leukemia. Front Pharmacol. 2020;11: 569843. https://doi.org/10.3389/fphar.2020.569843 .
doi: 10.3389/fphar.2020.569843
pubmed: 33381028
pmcid: 7768902
Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, et al. Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009;27:3141–7. https://doi.org/10.1200/jco.2008.20.4818 .
doi: 10.1200/jco.2008.20.4818
pubmed: 19451435